

March 26, 2025

Representative Daniel Nguyen House Committee On Economic Development, Small Business, and Trade 900 Court St. NE Salem, OR 97301

Dear Chair Nguyen and Members of the Committee:

Genentech strongly supports the **passage** of House Bill 2417.

Considered the founder of the biotech industry, Genentech has pursued groundbreaking science for nearly 50 years to discover and develop innovative medicines for people facing serious and life-threatening diseases. A member of the Roche Group since 2009, Genentech has one of the industry's largest R&D budgets, fueling the future of scientific discovery.

Genentech's investment in and commitment to Oregon dates back to 2006 with the purchase of 75 acres in Hillsboro. Today, Genentech employs nearly 900 people in the state of Oregon. Our presence includes two state-of-the-art manufacturing facilities in Hillsboro, where we have invested more than \$650 million in the creation of advanced therapeutics: Hillsboro Technical Operations, which opened in 2009, and Hillsboro Innovative Therapies, which opened in 2021. Additionally, since 2019, the city of Portland has been home to the Genentech Access Solutions Portland team. Over the past 27 years, Genentech has helped more than 3.3 million eligible patients access their medicines through programs like Genentech Access Solutions.

A key component to Genentech's success in Oregon is being part of a growing and vibrant bioscience ecosystem. That ecosystem begins with the support and sufficient funding of Oregon's Centers of Innovation Excellence and, more specifically, OTRADI.

OTRADI is a non-profit institute funded primarily by the State of Oregon under the umbrella of Business Oregon and the Oregon Innovation Council. OTRADI's mission is to fuel the economic development of Oregon's bioscience industry by translating innovative research into products and companies that benefit human health and create high-wage jobs for Oregon.

These companies and their innovations are key to driving future breakthroughs in the bioscience industry. With adequate support, they will continue to grow, employ Oregonians, and succeed in Oregon. For Genentech and other large bioscience companies, they are future innovation partners. More importantly, they develop and employ the workforce needed to support our future needs and help attract additional bioscience companies to Oregon, further expanding and strengthening our bioscience ecosystem.

As a board member of the Oregon Bioscience Association and an advocate for bioscience in Oregon, Genentech has long supported OTRADI and the exceptional work and companies it supports. **Today, I urge you to do the same by supporting the passage of HB 2417.**

Sincerely,

To-Japon

Tim Layton Director, State Government Affairs, Northwest Region Genentech, Inc. (206) 403-8224 <u>layton.timothy@gene.com</u>

<u>Genentech Oregon Sites</u>: Hillsboro Innovative Therapies and Hillsboro Technical Operations, Hillsboro, OR, and Portland Access Solutions, Portland, OR